Phentermine vs. Reductil (Sibutramine): Differences, Safety and Availability

Availability and use are different

In the United States, phentermine labeling describes short-term use as one part of a broader weight-reduction plan for selected patients. It requires a prescription and clinician oversight. This does not mean it is suitable for every person or intended for unsupervised weight loss.

The FDA says sibutramine was removed from the U.S. market after evidence indicated increased risk of heart attack and stroke. Avoid products sold online as Reductil or sibutramine unless a qualified local clinician and regulator can verify their lawful status and safety; an online product claim is not proof of approval.

Safety considerations

Phentermine can raise heart rate or blood pressure and has important contraindications, including certain cardiovascular conditions, uncontrolled hypertension, hyperthyroidism, glaucoma, and use near monoamine oxidase inhibitor treatment. Its label also cautions that combination weight-loss treatment has not been established as safe and effective.

Sibutramine can increase blood pressure or pulse and was withdrawn in the U.S. because of cardiovascular risk. Do not restart old supplies or take products that may contain sibutramine. If you have taken a suspected product and feel unwell, contact a healthcare professional or local poison service promptly.

Withdrawal and getting medical help

Talk with a prescriber before changing or stopping a prescribed weight-management medicine. If you used sibutramine or an unverified product, tell the clinician exactly what was taken and when. A healthcare professional can help assess symptoms and discuss safer, approved options.

Sources

• FDA: Sibutramine (Meridia) and associated risks
• DailyMed: phentermine prescribing information